

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): ~~Use of~~ A pharmaceutical composition for treating rosacea, comprising a rosacea treating effective amount of an antagonist of at least one receptor ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor, with the ~~exception of~~ proviso that the antagonist is not metronidazole, ~~for the preparation of a pharmaceutical composition for treating rosacea.~~

Claim 2 (Currently Amended): ~~[[Use]]~~ The composition according to Claim 1, ~~characterized in that the said compound~~ wherein the antagonist is an antagonist of two receptors ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 3 (Currently Amended): ~~[[Use]]~~ The composition according to Claim 1, ~~characterized in that the said compound~~ wherein the antagonist is an antagonist of three receptors ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 4 (Currently Amended): ~~[[Use]]~~ The composition according to Claim 1, ~~characterized in that the said compound~~ wherein the antagonist is an antagonist of four receptors ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 5 (Currently Amended): ~~[[Use]]~~ The composition according to Claim 1, ~~characterized in that the said compound wherein the antagonist~~ is an antagonist of five receptors ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 6 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 5, characterized in that the said compound~~ Claim 1, wherein the antagonist is at least one antagonist of the beta-adrenergic receptors and ~~in that it is chosen~~ selected from the group ~~comprising~~ consisting of metoprolol, esmolol, acebutolol, timolol, pindolol and labetalol.

Claim 7 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 5, characterized in that the said compound~~ Claim 1, wherein the antagonist is at least one antagonist of the AT1 receptor and ~~in that it is chosen~~ selected from the group ~~comprising~~ consisting of candesartan, cilxetil, losartan, irbesartan, telmisartan, valsartan and eprosartan.

Claim 8 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 5, characterized in that the said compound~~ Claim 1, wherein the antagonist is at least one antagonist of the 5-HT2 and 5-HT5 receptors and ~~in that it is chosen~~ selected from the group ~~comprising a compound chosen from the group comprising~~ consisting of ketanserin, trazodone and risperidone.

Claim 9 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 8, characterized in that the said pharmaceutical~~ Claim 1, wherein the composition is a dermatological composition for topical application.

Claim 10 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 9, characterized in that~~ Claim 1, wherein the composition is for treating at least one stage of rosacea.

Claim 11 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 10, characterized in that~~ Claim 1, wherein the composition is for treating the first stage of rosacea.

Claim 12 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 11, characterized in that~~ Claim 1, wherein the composition is for treating the second stage of rosacea.

Claim 13 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 12, characterized in that~~ Claim 1, wherein the composition is for treating the third stage of rosacea.

Claim 14 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 13, characterized in that~~ Claim 1, wherein the composition is for treating the fourth stage of rosacea.

Claim 15 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 14, characterized in that the said~~ Claim 1, wherein the composition contains from 0.0001% to 20% by weight, ~~preferably from 0.1% to 2% and more preferentially from about 0.75% to 1% by weight of the~~ ~~[[said]]~~ antagonist.

Claim 16 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 15, characterized in that the said composition also contains~~ Claim 1, further comprising another active agent chosen from the group of antibiotics, antibacterial agents, antiviral agents, antiparasitic agents, antifungal agents, anaesthetics, analgesics, antiallergic agents, retinoids, free-radical scavengers, anti-pruriginous agents, kerato-lytic agents, anti-seborrhoeic agents, antihistamines, sulfides, immunosuppressant products and anti-proliferative products.

Claim 17 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 16, characterized in that the composition contains~~ Claim 1, further comprising an additive chosen from the group of sequestrants, antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, dyes, common mineral or organic acids or bases, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, calmatives and skin-protecting agents, pro-penetrating agents and gelling agents, or a mixture thereof.

Claim 18 (New): The composition according to Claim 15, wherein the composition contains from 0.1% to 2% by weight of the antagonist.

Claim 19 (New): The composition according to Claim 18, wherein the composition contains from about 0.75% to 1% by weight of the antagonist.